MicroRNA-17 inhibits tumor growth by stimulating T-cell mediated host immune response

Oncoscience

Volumn 1, Issue 7, 2014, Pages 531-539

  Li, Haoran ^a,b   Gupta, Shaan ^a,b   Du, William W ^a,b   Yang, Burton B ^a,b  

^a Canada   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Immune response; microRNA; MiR 17; Stat3; T cell

Indexed keywords

EID: 84928733650     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.69     Document Type: Article

References (34)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1): 9-29.
2. Shah DJ and Dronca RS. Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma. Mayo Clinic proceedings. 2014; 89(4): 504-519.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892): 949-954.
4. Kortylewski M, Jove R and Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer metastasis reviews. 2005; 24(2): 315-327.
5. Sumimoto H, Imabayashi F, Iwata T and Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancerimmune evasion in human melanoma cells. The Journal of experimental medicine. 2006; 203(7): 1651-1656.
6. Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, Li L, Gimotty PA, Wilson M, Hayden J, Keeney F, Nathanson KL and Herlyn M. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene. 2014; 33(14): 1850-1861.
7. Shan SW, Lee DY, Deng Z, Shatseva T, Jeyapalan Z, Du WW, Zhang Y, Xuan JW, Yee SP, Siragam V and Yang BB. MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nature cell biology. 2009; 11(8): 1031-1038.
8. Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, Coukos G and Powell DJ, Jr. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20(1): 44-55.
9. Pinchuk LM and Filipov NM. Differential effects of age on circulating and splenic leukocyte populations in C57BL/6 and BALB/c male mice. Immunity & ageing: I & A. 2008; 5: 1.
10. Gajewski TF, Schreiber H and Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nature immunology. 2013; 14(10): 1014-1022.
11. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F and Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011; 29(6): 610-618.
12. Cui W, Liu Y, Weinstein JS, Craft J and Kaech SM. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity. 2011; 35(5): 792-805.
13. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P and Restifo NP. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009; 15(7): 808-813.
14. Kim EH and Suresh M. Role of PI3K/Akt signaling in memory CD8 T cell differentiation. Frontiers in immunology. 2013; 4: 20.
15. Li H and Yang BB. MicroRNA-regulated stress response in cancer and its clinical implications. Cell Cycle. 2013; 12(13): 1983-1984.
16. Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y and Yee C. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A. 2012; 109(12): 4592-4597.
17. Zhong G, Cheng X, Long H, He L, Qi W, Xiang T, Zhao Z and Zhu B. Dynamically expressed microRNA-15b modulates the activities of CD8+ T lymphocytes in mice with Lewis lung carcinoma. Journal of translational medicine. 2013; 11: 71.
18. Yang X, Du WW, Li H, Liu F, Khorshidi A, Rutnam ZJ and Yang BB. Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res. 2013; 41(21): 9688-9704.
19. Shan SW, Fang L, Shatseva T, Rutnam ZJ, Yang X, Du W, Lu WY, Xuan JW, Deng Z and Yang BB. Mature miR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7 and vimentin in different signal pathways. J Cell Sci. 2013; 126(Pt 6): 1517-1530.
20. Li H and Yang BB. Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2. Oncotarget. 2012; 3(12): 1653-1668.
21. Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezu T, Suzuki K, Inagaki A, Iida S and Ohyashiki K. Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood cancer journal. 2012; 2(1): e53.
22. Wong P, Iwasaki M, Somervaille TC, Ficara F, Carico C, Arnold C, Chen CZ and Cleary ML. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res. 2010; 70(9): 3833-3842.
23. Yu H, Kortylewski M and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature reviews Immunology. 2007; 7(1): 41-51.
24. Cao Q, Li YY, He WF, Zhang ZZ, Zhou Q, Liu X, Shen Y and Huang TT. Interplay between microRNAs and the STAT3 signaling pathway in human cancers. Physiological genomics. 2013; 45(24): 1206-1214.
25. Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, Yang Y, McEnery K, Jethwa K, Gjyshi O, Qiao W, Levine NB, Lang FF, Rao G, Fuller GN, Calin GA, et al. miR-124 inhibits STAT3 signaling to enhance T cellmediated immune clearance of glioma. Cancer Res. 2013; 73(13): 3913-3926.
26. Wu L, Bijian K and Shen SH. CD45 recruits adapter protein DOK-1 and negatively regulates JAK-STAT signaling in hematopoietic cells. Molecular immunology. 2009; 46(11-12): 2167-2177.
27. Saki N, Abroun S, Soleimani M, Mortazavi Y, Kaviani S and Arefian E. The roles of miR-146a in the differentiation of Jurkat T-lymphoblasts. Hematology. 2014; 19(3): 141-147.
28. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R and Huber LC. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circulation research. 2009; 104(10): 1184-1191.
29. Du WW, Fang L, Li M, Yang X, Liang Y, Peng C, Qian W, O'Malley YQ, Askeland RW, Sugg SL, Qian J, Lin J, Jiang Z, Yee AJ, Sefton M, Deng Z, et al. MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J Cell Sci. 2013; 126(Pt 6): 1440-1453.
30. Siragam V, Rutnam ZJ, Yang W, Fang L, Luo L, Yang X, Li M, Deng Z, Qian J, Peng C and Yang BB. MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11. Oncotarget. 2012; 3(11): 1370-1385.
31. Fang L, Du WW, Yang W, Rutnam ZJ, Peng C, Li H, O'Malley YQ, Askeland RW, Sugg S, Liu M, Mehta T, Deng Z and Yang BB. MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle. 2012; 11(23): 4352-4365.
32. Li H, Chang L, Du WW, Gupta S, Khorshidi A, Sefton M and Yang BB. Anti-microRNA-378a Enhances Wound Healing Process by Up-regulating Integrin beta-3 and Vimentin. Mol Ther. 2014.
33. Rutnam ZJ and Yang BB. The non-coding 3' UTR of CD44 induces metastasis by regulating extracellular matrix functions. J Cell Sci. 2012; 125(Pt 8): 2075-2085.
34. Liu F, Lv Q, Du WW, Li H, Yang X, Liu D, Deng Z, Ling W, Zhang Y and Yang BB. Specificity of miR-378a-5p targeting rodent fibronectin. Biochim Biophys Acta. 2013; 1833(12): 3272-3285.